Business Express is an online portal that covers the latest developments in the world of business and finance. From startups and entrepreneurship to mergers and acquisitions, Business Express provides reporting on the stories that matter most to business leaders and decision-makers.The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.
2021 08 18T145853Z 1 LYNXMPEH7H0Q4 RTROPTP 4 HEALTH CORONAVIRUS ISRAEL VACCINE - Business Express
FILE PHOTO: A vial and syringe are seen in front of a displayed Pfizer logo in this illustration taken January 11, 2021. REUTERS/Dado Ruvic/Illustration/File Photo

Third Pfizer dose 86% effective in over 60s, Israeli HMO says


TEL AVIV (Reuters) – A third dose of Pfizer/BioNTech’s COVID-19 vaccine was found to be 86% effective in people aged over 60, an Israeli healthcare provider said on Wednesday, citing initial results from a study of thousands of members.

Israeli HMO Maccabi, which covers around a quarter of the country’s 9.3 million population, compared results from 149,144 people aged over 60 who received their third dose at least a week ago against those from 675,630 more who had received only two doses, between January and February.

Some 37 people tested positive for coronavirus after their third jab, compared with 1,064 positive cases among those who had received only two doses, Maccabi said in a statement. The comparison groups had similar demographic profiles, it added.

Maccabi did not provide any information on the severity of the 37 positive cases, or whether they had any underlying conditions. The Health Maintenance Organisation (HMO) did not immediately respond to a request for comment.

Pfizer has said that its vaccine’s efficacy drops over time, and that a third dose showed significantly higher neutralising antibodies against the initial SARS-CoV-2 virus as well as against the Beta and highly infectious Delta variants.

Israel began administering third Pfizer doses last month to confront a surge in local infections driven by the Delta variant. Some 1.1 million eligible Israelis – people over 50, healthcare workers, and others – have received their third dose.

The United States and several European countries are expected to begin offering boosters to the elderly and people with weak immune systems, and some are considering whether to make a third dose available more widely.

Don't miss out on any breaking news or insightful opinions!
Subscribe to our free newsletter and stay updated on the go!


By submitting this form, you are consenting to receive marketing emails from: Global Banking & Finance Review. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email.

Nonetheless, Israeli health officials worry that cases will continue to mount given that another 1.1 million Israelis – around 11% of the population – remain unvaccinated. Severe cases have also continued to climb, mostly among the unvaccinated.

Health ministry data released on Wednesday, based on data per 100,000 people, showed 172 serious cases among unvaccinated people over 60, compared with 21 serious cases among vaccinated individuals in the same age group.

Dr. Anat Ekka Zohar of Maccabi said that the third dose “has again proved its effectiveness,” and had “demonstrated protection (against) the Delta variant”.

“The triple dose is the solution to curbing the current infection outbreak,” she said.

 

(Reporting by Rami Ayyub and Maayan Lubell; Editing by Hugh Lawson)

 

Recent Post: